Bioxcel Therapeutics, INC 8-K filings

BioXcel Therapeutics has amended its credit agreement, waiving a going concern qualification, and received Fast Track designation from the FDA for its cancer treatment program.

BioXcel Therapeutics is planning additional Phase 3 trials for BXCL501 in at-home settings for agitation related to dementia, bipolar disorders, and schizophrenia, while also reporting an estimated $61.6 million in cash as of January 31, 2024.

BioXcel Therapeutics has obtained new patents for its dexmedetomidine-based agitation treatments, potentially extending market exclusivity until 2043.